Clinical

Dataset Information

0

Retrospective study of trifluridine/tipiracil hydrochloride plus bevacizumab for vulnerable patients with previously treated metastatic colorectal cancer(WJOG14520G)

ABSTRACT: Primary outcome(s): Overall survival

DISEASE(S): Previously Treated Metastatic Colorectal Cancer

PROVIDER: 2723660 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Json Xml

Similar Datasets

Unknown Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study.
| S-EPMC8064512 | biostudies-literature
Unknown Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G).
| S-EPMC10403909 | biostudies-literature
Unknown TRIFLURIDINE/TIPIRACIL (FTD/TPI) with or without bevacizumab in previously treated patients with esophago-gastric adenocarcinoma, a randomised phase III trial.
| S-EPMC10940909 | biostudies-literature
Unknown Predictive marker for response to trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer patients.
| S-EPMC11694457 | biostudies-literature
Unknown Trifluridine/tipiracil plus ramucirumab in gastric cancer.
| S-EPMC8447873 | biostudies-literature
Unknown Effect of neutropenia on survival outcomes of patients with metastatic colorectal cancer receiving trifluridine/tipiracil plus bevacizumab.
| S-EPMC8456503 | biostudies-literature
Unknown A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G.
| S-EPMC10963434 | biostudies-literature
Unknown Pooled safety analysis of two phase 3 studies investigating trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer.
| S-EPMC11779617 | biostudies-literature
Unknown Safety and efficacy of trifluridine/tipiracil +/- bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial.
| S-EPMC11739593 | biostudies-literature
Unknown A phase II study of intrapatient dose escalation of biweekly trifluridine/tipiracil plus bevacizumab for colorectal cancer (E-BiTS study).
| S-EPMC12414899 | biostudies-literature